Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript09/12/2025
Share Facebook Twitter LinkedIn Pinterest Email Marvell: The Bull Case Revolves Around Optics, Not ASICsLike this:Like Loading...Related ASICs Bull case Marvell optics revolves
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript09/12/2025